Clarivate Plc reports developments in data, analytics and workflow software for academia and government, intellectual property, and life sciences and healthcare. Its news commonly covers earnings, subscription and recurring revenue trends, cash flow and leverage actions, and progress under its operating improvement initiatives.
Company updates also focus on AI-enabled research and decision-support products, including Web of Science Research Intelligence, Nexus Connect, Cortellis Regulatory Intelligence, Derwent-based patent analytics and other Clarivate data assets. Recurring announcements address institutional research intelligence, academic library workflows, regulatory intelligence for life sciences teams, intellectual property benchmarks and investor conference appearances.
Clarivate Plc (NYSE: CLVT) has appointed Bar Veinstein as President of Academia & Government, effective April 24, 2023. Veinstein, who previously served as CEO of Taranis, brings extensive experience in AI and cloud technologies. His prior role as President of Ex Libris Group saw him expand its reach to over 7,500 institutions globally. This appointment positions Clarivate to enhance growth within its Academia & Government segment, aiming to support educational institutions in achieving research excellence. The announcement follows a similar appointment of Gordon Samson as President of Intellectual Property, indicating a strategic focus on leadership within key market segments.
Clarivate (NYSE: CLVT) announces a special series by BioWorld titled Radiopharmaceuticals: The next big disrupter, focusing on the emerging field of radiopharmaceutical therapy, projected to reach $12 billion by 2030. This eight-part series investigates new uses and alternatives in cancer treatment, highlighting the evolution from one therapy in the 1950s to a range of options today that deliver targeted radiation to tumors. Key topics include the challenges facing radiopharma stakeholders, the industry's growth potential, and regulatory hurdles. Lynn Yoffee, Publisher of BioWorld, emphasizes the rapid advancements and substantial investments, including $6 billion by Novartis AG. The series contributes valuable insights into the radiopharmaceutical pipeline and how these therapies could transform cancer treatment.
Clarivate Plc (NYSE: CLVT) announced the appointment of Gordon Samson as President of its Intellectual Property (IP) market segment, effective April 1, 2023. Previously serving as Chief Product Officer, Samson aims to drive growth in the IP sector. The company also nominated Dr. Saurabh Saha for election to the Board at the Annual General Meeting on May 4, 2023. Dr. Saha, currently CEO of Centessa Pharmaceuticals (NASDAQ: CNTA), brings extensive experience in pharmaceuticals and biotech. This strategic move is to enhance leadership as Clarivate executes its growth strategy in Life Sciences & Healthcare.
Clarivate Plc (NYSE: CLVT) has announced the appointment of Gordon Samson as President of its Intellectual Property market segment, effective April 1, 2023. This new role aims to enhance growth within the IP sector. Additionally, Dr. Saurabh Saha has been nominated for election as an Independent Director at the upcoming 2023 Annual General Meeting on May 4, 2023. Dr. Saha, currently CEO of Centessa Pharmaceuticals (NASDAQ: CNTA), brings extensive experience in the pharmaceutical and biotech fields. Clarivate's CEO, Jonathan Gear, expressed confidence in Samson's ability to drive innovation and growth.
On March 13, 2023, Clarivate Plc (NYSE: CLVT) announced that Jonathan Collins, Executive Vice President and CFO, will present at the BofA Securities 2023 Information & Business Services Conference on March 16, 2023, at 9:45 am Eastern Time. The live webcast of the presentation will be accessible online and available for replay afterward. Clarivate is a leading global information services provider specializing in connecting people and organizations to trustworthy intelligence across various sectors, including Academia & Government, Life Sciences & Healthcare, and Intellectual Property. For more details, visit clarivate.com.
Clarivate reported a strong growth in Q4 and full-year 2022 financial results, with revenues of $675.3 million in Q4, marking a 20.4% increase, and total revenues of $2.66 billion for the full year, up 41.7%. The increase in revenue was largely attributed to the acquisition of ProQuest. However, a significant non-cash goodwill impairment led to a net loss of $4.04 billion for the year. Despite challenges, adjusted EBITDA rose to $1.11 billion, indicating robust operational performance. The company is set to discuss its growth plans during an Investor Day on March 9, 2023.
Clarivate Plc (NYSE:CLVT) will ring the opening bell at the New York Stock Exchange on March 6, 2023. The company announced its Investor Day conference for March 9, 2023, which will be streamed live due to limited in-person capacity. CEO Jonathan Gear highlighted the company’s progress in transforming the business and enhancing shareholder value. The opening bell will take place at 9:30 a.m. ET on March 6, and the Investor Day will run from 9:00 a.m. to 12:00 p.m. ET on March 9. Live streams will be available on both the NYSE and Clarivate's investor relations website.
On February 22, 2023, Clarivate Plc (NYSE: CLVT) and the KAIST Innovation Strategy and Policy Institute released a report analyzing the global innovation landscape of the AI chip industry. The report highlights a shift from mass-produced chips to specialized, mission-oriented processors due to rising demand for efficient data processing. Key findings indicate that the U.S. and Mainland China dominate AI chip patents, with the U.S. exhibiting higher patent quality. The report emphasizes collaboration between universities and industry for R&D innovation, proposing strategies for the future AI chip market.
Summary not available.
On February 9, 2023, Clarivate (NYSE:CLVT) announced the integration of the Preprint Citation Index™ into the Web of Science™ platform. This new feature allows researchers to access nearly two million preprints from various reputable repositories such as arXiv, bioRxiv, and chemRxiv alongside peer-reviewed content. The index facilitates quicker research processes by linking preprints to final articles and displaying them on researchers' profiles. The initiative aims to enhance scientific collaboration and speed up advancements in global research challenges, further establishing Clarivate as a leader in academic publishing.